KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Medpace Holdings (MEDP) Payables (2016 - 2025)

Historic Payables for Medpace Holdings (MEDP) over the last 11 years, with Q3 2025 value amounting to $26.5 million.

  • Medpace Holdings' Payables rose 122.9% to $26.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $26.5 million, marking a year-over-year increase of 122.9%. This contributed to the annual value of $32.5 million for FY2024, which is 206.78% up from last year.
  • Per Medpace Holdings' latest filing, its Payables stood at $26.5 million for Q3 2025, which was up 122.9% from $43.3 million recorded in Q2 2025.
  • In the past 5 years, Medpace Holdings' Payables ranged from a high of $278.5 million in Q2 2022 and a low of $21.3 million during Q1 2021
  • Moreover, its 5-year median value for Payables was $29.0 million (2023), whereas its average is $62.8 million.
  • As far as peak fluctuations go, Medpace Holdings' Payables skyrocketed by 109394.67% in 2022, and later plummeted by 8395.77% in 2024.
  • Over the past 5 years, Medpace Holdings' Payables (Quarter) stood at $25.7 million in 2021, then skyrocketed by 223.5% to $83.1 million in 2022, then crashed by 61.64% to $31.9 million in 2023, then grew by 2.07% to $32.5 million in 2024, then decreased by 18.46% to $26.5 million in 2025.
  • Its Payables stands at $26.5 million for Q3 2025, versus $43.3 million for Q2 2025 and $61.3 million for Q1 2025.